Trilaciclib
Back to searchMolecule Structure
Scientific Name
Trilaciclib
Description of the Drug
Trilaciclib is a CDK4 and CDK6 inhibitor to reduce the risk of chemotherapy induced myelosuppression.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15442
http://www.drugbank.ca/drugs/DB15442
Brand Name(s)
Not Available
Company Owner(s)
G1 Therapeutics Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Cyclin-dependent kinase 6 | SINGLE PROTEIN | INHIBITOR | CHEMBL2508 |
| Cyclin-dependent kinase 4 | SINGLE PROTEIN | INHIBITOR | CHEMBL331 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL10082028 |
| Human Metabolome Database | HMDB0304899 |
| DrugBank | DB15442 |
| PubChem | 68029831 |
| BindingDB | 253928 |
| DrugCentral | 5442 |
| ChemicalBook | CB73353991 |
| Guide to Pharmacology | 9626 |
